Bioniche Life chemistry Inc. has if and only if an update on its Phase III clinical program
approximate Urocidin(TM) in the therapy of bladder cancer. On March 31st, the Company announced that recruitment had been completed in its initial Phase III registration trial evaluating Urocidin in the care of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current test immunotherapy - Bacillus Calmette-Guérin (BCG).

More: - Read the rest here